• br Materials and methods br Results br Discussions

  2021-11-10

  

  Materials and methods Results Discussions The treated tannery effluent (both MF and MF+RO treated) was free from most of the organic and inorganic loadings as reflected from the values of COD, BOD, total kjeldahl nitrogen (TKN) and sulfides etc. Toxicity study of the effluent (both treated

• Concerning the molecular mechanisms underlying transcription

  2021-11-10

  

  Concerning the molecular mechanisms underlying transcriptional regulation of the GSTP1-1 gene expression we and others have characterized structural and functional properties of the human GSTP1-1 promoter. GSTP1-1 gene promoter activity is driven by a TATA-box [16] as well as Spl [16], [17], AP-1 [1

• Studies with GSNOR knockout mice reported decreased CD cells

  2021-11-10

  

  Studies with GSNOR knockout mice reported decreased CD4+ Mifepristone and increased CD19+ cells (B-cell) in the blood [31] as well as demyelination, neurodegeneration, and neuropathic pain [29]. To understand the basis of these differences in immune function of GSNOR knockout mice and GSNO treated

• A few methods have been

  2021-11-10

  

  A few methods have been developed to separate and prepare compounds from L. chinensis, such as silica gel column chromatography [5,6] and high-performance liquid chromatography (HPLC) [7]. Silica gel column chromatography is still used for its simple equipment and low cost. However, this method is o

• GLP is an intestinal peptide

  2021-11-10

  

  GLP-1 is an intestinal peptide hormone that is released by the gut following ingestion of food, particularly Closantel Sodium and fats. Following its release, GLP-1 stimulates pancreatic β-cells to secrete insulin (Hirasawa et al., 2005, Covington et al., 2006). Originally, GLP-1 acted in a similar

• VU 591 hydrochloride The DNA cleavage activity assay in the

  2021-11-10

  

  The DNA cleavage activity assay in the present study also demonstrated the DNA glycosylase activities of SMUG1, NEIL1, TDG, and NTHL1 for 5OHU paired with A. While our findings on the activities of SMUG1 and NEIL1 were consistent with the results reported from previous studies [25], [50], the activi

• Our overall goal is to develop selective compounds

  2021-11-10

  

  Our overall goal is to develop selective compounds for low-affinity/high-capacity transporters inhibitors (i.e. OCT1–3 and PMAT), and provide the field with much needed, specific pharmacological tools to study these transporters. In our initial efforts, we synthesized halogen substituted analogs and

• As cardiovascular disease accounts for

  2021-11-10

  

  As cardiovascular disease accounts for the majority of deaths in subjects with T2D, it is imperative that we better characterize the cardiovascular risks and benefits of the various therapies we prescribe to these individuals to control their glycemia. Indeed, the potential to identify subsets of di

• Work in the Ruiz i Altaba lab

  2021-11-10

  

  Work in the Ruiz i Altaba lab was funded by grants from the Swiss National Science Foundation, the Ligue Suisse Contre le Cancer, the European FP7 Marie-Curie Initial Training Network HEALING, a James McDonnell Foundation 21st Century Science Initiative in Brain Cancer-Research Award and funds from

• br Conflicts of interests br Acknowledgements We thank

  2021-11-10

  

  Conflicts of interests Acknowledgements We thank Drs. T. Tomita and T. Iwatsubo (Tokyo University, Tokyo, Japan) for anti-presenilin 1-CTF antiserum, Dr. A. Takashima (Gakushuin University, Tokyo, Japan) for anti-Pen-2 antiserum and the laboratory members for helpful comments and discussion. M

• br The bile acid farnesoid X

  2021-11-10

  

  The “bile acid” farnesoid X receptor (FXR) The Farnesoid X Receptor (FXR) is a ligand-activated nuclear receptor belonging to the Nuclear Receptor superfamily of transcription factors exploiting various crucial functions in mammalian physiology, including reproduction, development and metabolism

• br Financial support This work was

  2021-11-10

  

  Financial support This work was supported by Fondation pour la Recherche Médicale (Equipe labellisée, DEQ20150331724), Inserm, University of Lille, and Agence Nationale pour la Recherche (ANR-10-LBEX-46 and ANR-10-INBS-08; ProFI project, “Infrastructures Nationales en Biologie et Santé”; “Investi

• The receptor binding assay used in our previous study demons

  2021-11-10

  

  The receptor binding assay used in our previous study demonstrated that propofol competitively binds to FPR1, thus blocking the downstream signal transduction of FPR1 and inhibiting neutrophil immune activities [8]. In this study, we assessed the pharmacological action of fMMYALF in the presence of

• The current lack of effective treatments for

  2021-11-10

  

  The current lack of effective treatments for primary or metastatic UM leaves a large therapeutic gap for patients and clinicians underscoring an urgent need for the identification of additional pharmacological targets for therapeutic intervention. As YAP-targeting strategies have remained elusive th

• br Introduction Thrombosis is one of the leading causes

  2021-11-10

  

  Introduction Thrombosis is one of the leading causes of deaths in the cardiovascular diseases such as myocardial infarction (MI), unstable 2768 sale and acute coronary syndrome (ACS) in developed countries [1], [2]. It is estimated that venous thromboembolism (VTE) afflicts about 1 million (1–2 p

16630 records 588/1109 page Previous Next First page 上5页 586587588589590 下5页 Last page